Levetiracetam Kern Pharma (Levetiracetam)

Levetiracetam is an antiepileptic medication that reduces seizure activity by modulating neuronal excitability.

• Partial seizures: Improves seizure control and reduces frequency in patients with focal onset seizures, including simple and complex partial seizures.
• Generalized tonic-clonic seizures: Helps prevent convulsive episodes in individuals with primary generalized seizures, reducing the risk of injury.
• Myoclonic seizures: Decreases occurrence of sudden muscle jerks associated with myoclonic epilepsy, enhancing daily functioning.

• Levetiracetam binds selectively to the synaptic vesicle protein SV2A, a key regulator of neurotransmitter release. This interaction modulates synaptic vesicle exocytosis, stabilizing neuronal firing and reducing hyper‑excitability. By influencing calcium‑dependent processes, the drug diminishes the propagation of abnormal electrical activity without directly affecting ion channels or G‑protein pathways, contributing to its broad antiepileptic efficacy.

Levetiracetam may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Dizziness: Light‑headedness or balance disturbances that may affect daily activities.
• Fatigue: Persistent tiredness that can reduce alertness and physical performance.
• Nausea: Stomach upset, sometimes accompanied by vomiting, especially after dose initiation.
• Irritability: Mood changes such as agitation or increased nervousness.

Serious or Rare Side Effects

• Severe allergic reaction: Rash, swelling of face or limbs, or difficulty breathing requiring immediate medical attention.
• Mood disorders: Emergence of depression, anxiety, or suicidal thoughts that should be reported promptly.
• Stevens‑Johnson syndrome: A rare, potentially life‑threatening skin reaction characterized by blistering and detachment.

When prescribing Levetiracetam, clinicians should consider several precautionary measures to ensure safe use.

• Renal impairment: Adjust dose in patients with reduced kidney function.
• Hepatic dysfunction: Monitor liver enzymes in patients with liver disease.
• Psychiatric history: Observe for mood changes or suicidal ideation.
• Concomitant CNS depressants: Use caution as combined effects may increase sedation.
• Pregnancy and breastfeeding: Evaluate risks versus benefits; data are limited.
• Store at ambient temperature: Keep below 25 °C in the original container, protect from moisture.

Levetiracetam can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

• Carbamazepine: May reduce levetiracetam plasma levels, decreasing effectiveness.
• Phenobarbital: Similar enzyme‑inducing effect leading to lower drug concentrations.
• Phenytoin: Can lower levetiracetam exposure, risking breakthrough seizures.

Moderate Interactions (Monitor Closely)

• Alcohol: Combined use may increase central nervous system depression.
• Sedative antihistamines: May enhance drowsiness.
• Opioids: Potential additive sedation and respiratory depression.